PCSA — Processa Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $4.66m
- -$4.25m
- 24
- 48
- 37
- 29
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.63 | ||
| Price to Tang. Book | 0.63 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -113.74% | ||
| Return on Equity | -103.29% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on utilizing its regulatory science approach, including the principles associated with food and drug administration (FDA’s) Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation Chemotherapy (NGC) oncology drug products. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine, resulting in a positive response in gemcitabine patients and some gemcitabine treatment-resistant patients. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38).
Directors
- David Young CHM (68)
- Wendy Guy FDR (57)
- Sian Bigora FDR (61)
- James Stanker CFO (63)
- R. Michael Floyd COO (65)
- Patrick Lin OTH (56)
- Khalid Islam DRC (65)
- Geraldine Pannu IND (51)
- Virgil Thompson IND (82)
- Justin Yorke IND (55)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- March 29th, 2011
- Public Since
- October 7th, 2013
- No. of Shareholders
- 187
- No. of Employees
- 13
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 2,858,007
- Address
- 7380 Coca Cola Dr Ste 106, HANOVER, 21076-1789
- Web
- https://www.processapharmaceuticals.com/
- Phone
- +1 4437763133
- Auditors
- BD & Company, Inc
Upcoming Events for PCSA
Processa Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Processa Pharmaceuticals Inc Earnings Release
Q3 2024 Processa Pharmaceuticals Inc Earnings Release
Similar to PCSA
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Aptorum
NASDAQ Capital Market
FAQ
What is the Processa Pharmaceuticals share price?
As of Today at 22:45 UTC, shares in Processa Pharmaceuticals are trading at $1.96. This share price information is delayed by 15 minutes.
How has the Processa Pharmaceuticals share price performed this year?
Shares in Processa Pharmaceuticals last closed at $1.96 and the price had moved by +237.99% over the past 365 days. In terms of relative price strength the Processa Pharmaceuticals share price has outperformed the S&P500 Index by +168.95% over the past year.
What are the analyst and broker recommendations for Processa Pharmaceuticals?
The overall consensus recommendation for Processa Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Processa Pharmaceuticals dividend yield?
Processa Pharmaceuticals does not currently pay a dividend.
Does Processa Pharmaceuticals pay a dividend?
Processa Pharmaceuticals does not currently pay a dividend.
When does Processa Pharmaceuticals next pay dividends?
Processa Pharmaceuticals does not currently pay a dividend.
How do I buy Processa Pharmaceuticals shares?
To buy shares in Processa Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Processa Pharmaceuticals?
As of the previous close price of $1.96, shares in Processa Pharmaceuticals had a market capitalisation of $5.60m.
Where are Processa Pharmaceuticals shares listed?
Here are the trading details for Processa Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PCSA
What kind of share is Processa Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Processa Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Processa Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Processa Pharmaceuticals is $44.00. That is 2144.9% above the last closing price of $1.96.
Analysts covering Processa Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$3.90 for the next financial year.
What is the trend in the Processa Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Processa Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +281.08%.
As of the last closing price of $1.96, shares in Processa Pharmaceuticals were trading +44.45% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Processa Pharmaceuticals PE Ratio?
The Processa Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.96.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Processa Pharmaceuticals?
Processa Pharmaceuticals' management team is headed by:
- David Young - CHM
- Wendy Guy - FDR
- Sian Bigora - FDR
- James Stanker - CFO
- R. Michael Floyd - COO
- Patrick Lin - OTH
- Khalid Islam - DRC
- Geraldine Pannu - IND
- Virgil Thompson - IND
- Justin Yorke - IND